Sign In
Buy TENX
$12.25
+0.250 (+2.08%)
At Close: Jun 22, 2026
Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript
09:31pm, Thursday, 13'th Nov 2025
Tenax Therapeutics, Inc. ( TENX ) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF November 13, 2025 4:30 PM EST Company Participants Christopher Giordano - CEO, Preside
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 12'th Nov 2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
07:00am, Thursday, 06'th Nov 2025
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
07:00am, Monday, 03'rd Nov 2025
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
07:00am, Tuesday, 16'th Sep 2025
Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Prov
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
07:00am, Thursday, 28'th Aug 2025
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 13'th Aug 2025
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 14'th May 2025
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts
04:29pm, Wednesday, 16'th Apr 2025
Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-m
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 31'st Mar 2025
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 25'th Mar 2025
Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations t
Tenax Therapeutics Announces $25 Million Private Placement
08:47am, Wednesday, 05'th Mar 2025
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
08:00am, Monday, 03'rd Mar 2025
CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focus
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
09:00am, Friday, 31'st Jan 2025
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focuse
